Eton Pharmaceuticals, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has launched Galzin (zinc acetate) capsules. Galzin is FDA-approved for the maintenance treatment of patients with Wilson disease who have been initially treated with a chelating agent. It is the only FDA-approved zinc therapy for Wilson disease.
“We are excited to launch Galzin with our dedicated sales force and robust Eton Cares patient support services. Due to historic availability and affordability challenges, many patients have turned to unapproved compounded products or over-the-counter supplements to manage their Wilson disease. We are dedicated to increasing both access to and awareness of this critical medication. Through Eton Cares, we intend to ensure that every patient that needs Galzin will have access to it,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “As part of our commitment to the Wilson disease community, Eton is also actively investing in further research and development in an effort to drive meaningful advancements in treatment.”
“Galzin is an important medication for Wilson disease patients, and we look forward to partnering with Eton to ensure patients have continued access to this drug,” said Rhonda Rowland, President, Wilson Disease Association.
Galzin is now available exclusively through Optime Care, a specialty pharmacy dedicated to helping patients with rare diseases manage their conditions. Optime Care will administer the Eton Cares Program in partnership with Eton Pharmaceuticals. The program will provide prescription fulfillment, insurance benefits investigation, educational support, and qualified patient financial assistance, along with other services designed to help eligible patients access treatment. Eton Cares will offer $0 co-pay for all eligible patients.
